User:Mr. Ibrahem/Factor VIII (medication)

From Wikipedia, the free encyclopedia
Factor VIII
A depiction of factor VIII
Clinical data
Trade namesAafact, Kovaltry, others[1]
Other namesoctocog alfa
AHFS/Drugs.comMonograph
Routes of
administration		Intravenous (IV)
Legal status
Legal status
  • US: ℞-only
  • In general: ℞ (Prescription only)

Factor VIII is a medication used to treat and prevent bleeding in people with hemophilia A and other causes of low factor VIII.[3][4] Certain preparations may also be used in those with von Willebrand's disease.[4] It is given by slow injection into a vein.[3]

Side effects include skin flushing, shortness of breath, fever, and red blood cell breakdown.[3][4] Allergic reactions including anaphylaxis may occur.[4] It is unclear if use during pregnancy is safe for the baby.[5] A purified factor VIII concentrate is made from human blood plasma.[4] A recombinant version is also available.[3] People may develop antibodies to factor VIII such that this medication becomes less effective.[5]

Factor VIII was first identified in the 1940s and became available as a medication in the 1960s.[6][7] Recombinant factor VIII was first made in 1984 and approved for medical use in the United States in 1992.[8][9] It is on the World Health Organization's List of Essential Medicines.[10] The wholesale cost in the developing world is about US$119–497 per 500 IU vial.[11]

References[edit]

  1. ^ "Coagulation Factor VIII, Human". www.drugs.com. Archived from the original on 9 January 2017. Retrieved 8 January 2017.
  2. ^ "Single Drug Information – International Medical Products Price Guide". mshpriceguide. Archived from the original on 28 August 2021. Retrieved 16 August 2020.
  3. ^ a b c d World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. pp. 259–60. hdl:10665/44053. ISBN 9789241547659.
  4. ^ a b c d e British National Formulary : BNF 69. British Medical Association. 2015. p. 171. ISBN 978-0857111562.
  5. ^ a b "Alphanate – Summary of Product Characteristics (SPC) – (eMC)". www.medicines.org.uk. Archived from the original on 9 January 2017. Retrieved 8 January 2017.
  6. ^ Potts, D.M. (2011). Queen Victoria's Gene: Haemophilia and the Royal Family (Chapter 5). The History Press. ISBN 978-0752471969. Archived from the original on 2017-01-09.
  7. ^ Sibinga, Cees Smit; Das, P.C.; Overby, L.R. (2012). Biotechnology in blood transfusion: Proceedings of the Twelfth Annual Symposium on Blood Transfusion, Groningen 1987, organized by the Red Cross Blood Bank Groningen-Drenthe. Springer Science & Business Media. p. 224. ISBN 978-1461317616. Archived from the original on 2017-01-09.
  8. ^ Buckel, P. (2012). Recombinant Protein Drugs. Birkhäuser. p. 79. ISBN 978-3034883467. Archived from the original on 2017-01-09.
  9. ^ Hillyer, Christopher D. (2006). Blood Banking and Transfusion Medicine: Basic Principles & Practice. Elsevier Health Sciences. p. 353. ISBN 0443069816. Archived from the original on 2017-01-09.
  10. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  11. ^ "Factor Viii". International Drug Price Indicator Guide. Archived from the original on 21 November 2018. Retrieved 8 December 2016.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Factor_VIII_(medication)&oldid=1141822135"